8 completed, 1 not yet recruiting, 1 recruiting. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Iltoo Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders ILT-101 ld-(IL2), NaCl (0,9%) - Autism Spectrum Disorder | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 22 | 2026-10-01 | 2026-05-15 |
| Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Cyclosporin, ILT101, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 24 | 2022-09-21 | 2026-09-09 |
| Low-dose Interleukin-2 in Women With Unexplained Miscarriages low-dose IL-2 - Recurrent Miscarriage | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 18 | 2021-01-05 | 2025-09-12 |
| Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 1: ILT101, 2: Placebo Comparator - COVID 19 | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2020-10-23 | 2021-10-04 |
| Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder ILT101, Placebos - Bipolar Depression | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 14 | 2020-06-15 | 2026-04-06 |
| Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers ILT101, Placebo - Healthy Volunteers | Phase 1 | Completed | Assistance Publique - Hôpitaux de Paris | 40 | 2019-06-06 | 2021-12-30 |
| Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy ILT-101 ld-(IL2) - Allergic Rhinoconjunctivitis to Birch Pollen, With a Positive Skin Prick Test to Birch Pollen | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 24 | 2019-02-01 | 2025-09-16 |
| ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) ILT-101, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | Iltoo Pharma | 100 | 2017-01-18 | 2019-03-05 |
| Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes rhIL-2, Placebo - Type 1 Diabetes | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 141 | 2015-06-01 | 2023-08-14 |
| Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Interleukin 2 - Rheumatoid Arthritis, Ankylosing Spondylitis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 81 | 2014-01-06 | 2021-07-20 |
Diabetes Mellitus (2) · Diabetes Mellitus, Type 1 (2) · Lupus Erythematosus, Systemic (2) · Abortion, Habitual (1) · Abortion, Spontaneous (1) · Aortic Arch Syndromes (1) · Arthritis, Rheumatoid (1) · Autism Spectrum Disorder (1) · Behcet Syndrome (1) · Bipolar Disorder (1) · COVID-19 (1) · Cholangitis, Sclerosing (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Granulomatosis with Polyangiitis (1)
Interleukin-2 (5) · Cyclosporine (1)
France (10) · Germany (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Italy (1) · Mauritius (1) · Mexico (1) · Netherlands (1) · Portugal (1) · Romania (1) · Spain (1) · Sweden (1) · Switzerland (1)
David Klatzmann, Pr (2) · David Klatzmann, MD (1) · David Klatzmann, MD, Ph.D (1) · David Klatzmann, MD, Ph.D. (1) · David Klatzmann, MD, PhD (1) · Gilles Kayem, Pr (1) · Marion Leboyer, Pr (1) · Roberta Lorenzon, MD (1)
PMID 30472651, PMID 35973803, PMID 38367846, PMID 39242054, PMID 40329764, PMID 42822480
2018 (2), 2016 (1), 2025 (1)